Firazyr (icatibant)
- Region
- 🇪🇺 EU
- Active substance
- icatibant
- Company
- Takeda Pharmaceuticals International AG
- Status
- Authorised
- Therapeutic area
- Angioedemas, Hereditary
- CHMP opinion
- Thu 24 Apr 2008
- EU approval
- Fri 11 Jul 2008
- Application
- EMEA/H/C/000899
- ATC
- B06AC02
- Official record
- www.ema.europa.eu
Indication
Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Icatibant Accord Authorised · Accord Healthcare S.L.U.
Follow Firazyr
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.